BioWorld MedTech

June 2, 2010

Deals roundup: Covidien to pay $2.6 billion for ev3, sell sleep business

In an effort to boost its presence in the vascular market, Covidien (Dublin, Ireland) said Tuesday it would buy ev3 (Plymouth, Minnesota) for $22.50 a share in cash, or $2.6 billion. (Medical Device Daily) Read More

St. Jude Medical reinvigorates its cardiovascular business

Washington roundup: FDA again claims authority over drugs-of-abuse test kits

International report: Elekta acquires Resonant Medical for $30M in cash

Financings roundup: National Health Investors in $20M funding accord with CFG

MDD's food for med tech thought

Agreements/contracts: Naples Diagnostic to use IntelePACS mammography

Court report: Applied gets settlement against false advertising

Med-Tech Notes

Product Briefs

People in the News

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...